Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 8Advanced Solid Tumor 7Squamous Cell Carcinoma of Head and Neck 5Neoplasm Metastasis 5Colorectal Neoplasms 5Stomach Neoplasms 4Melanoma 4Carcinoma, Hepatocellular 4Solid Tumor 3Solid Tumors 2Lymphoma 2Head and Neck Neoplasms 2Esophageal Squamous Cell Carcinoma 2Carcinoma, Renal Cell 2Advanced Solid Tumors 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Testicular Germ Cell Tumor 1Skin Neoplasms 1Simpson-Golabi-Behmel syndrome 1Sarcoma 1Recurrence 1Rectal Neoplasms 1Pancreatic Neoplasms 1Pancreatic Ductal Adenocarcinoma 1Neuroendocrine Tumors 1Neoplasms 1Nasopharyngeal Carcinoma 1Muscle Invasive Bladder Cancer 1

Interventions

toripalimab 1tislelizumab 1sintilimab 1pembrolizumab 1durvalumab 1Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × High-Risk Resectable NSCLC × tislelizumab × Clear all
NCT03732664 2023-03-24

ICIs Neoadjuvant Therapy in Resectable Non-Small-Cell Lung Cancer

Second Affiliated Hospital, School of Medicine, Zhejiang University

Phase 1 Completed
27 enrolled
Thoracic

High-Risk Resectable NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡